ArticleBMC pregnancy and childbirth2025
The blocking efficacy and safety of tenofovir disoproxil fumarate tablets on mother-to-child transmission in pregnant women with high serum HBV DNA load: a retrospective cohort study.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to evaluate the efficacy and safety of using/not using the antiviral drug tenofovir disoproxil fumarate (TDF) in preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) among pregnant women with high serum HBV DNA viral loads.
methodsThis retrospective study included 512 pregnant women with HBV infection and a high serum HBV DNA load (> 2 × 10
resultsBefore delivery, serum HBV DNA, HBsAg, HBeAg, and ALT levels decreased in both groups, with significantly greater reductions in the TDF-treated group (P < 0.05). No significant differences were observed in TC levels, adverse drug reactions, cesarean section rates, or adverse pregnancy outcomes (P > 0.05). the HBV DNA, HBsAg, and HBeAg positivity rates of newborns were significantly lower in the TDF-treated group than those in the TDF-unexposed group (P < 0.05). Neonatal body mass index, 1-min Apgar scores, and adverse neonatal outcomes did not differ significantly between groups (P > 0.05).
conclusionTDF tablets can prevent MTCT of HBV in pregnant women with high HBV DNA loads. The treatment increases the seroconversion rates of HBV DNA, HBeAg, and HBsAg in mothers and infants, and shows a favorable safety profile without severe adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.